Zoetis Inc. (ZTS) exhibits 71.8% gross margins and 25.7% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 10.3x enterprise multiple and 6.9% implied options volatility.
Sustained 71.8% gross profitability converts into 34.4% operating margin and 25.7% ROIC, outpacing sector cost of capital.
ROIC: 25.7% // GM: 71.8%YoY revenue trajectory of +2.3% paired with 7.01% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +2.3% // FCF YLD: 7.01%Altman Z-Score of 4.53 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 4.53 // F-SCORE: 7/9Trading at 12.2x trailing P/E (11.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 12.2x // EV/EBITDA: 10.3xOptions market prices a ±6.9% implied move with a 0.65 put/call ratio around $77.00 max pain.
IMPL MOVE: ±6.9% // P/C: 0.65Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 28.2% net margins.
NET MARGIN: 28.2% // D/E: 2.65x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ZTS & activate live FRED threshold breach alerts.